Valuation: Syros Pharmaceuticals, Inc.

Market Cap 6.17M 5.62M 5.17M 4.71M 8.83M 571M 9.28M 62.98M 25.03M 312M 23.14M 22.65M 979M P/E 2022
-0.48x
P/E 2023 -1.34x
Enterprise Value -71.28M -64.93M -59.83M -54.42M -102M -6.6B -107M -728M -289M -3.61B -267M -262M -11.32B EV / Sales 2022
-4.44x
EV / Sales 2023 12.6x
Free-Float
100%
Yield 2022 *
-
Yield 2023 -
Current month-75.00%
1 month-75.00%
6 months-50.00%
Current year-71.43%
1 week 0
Extreme 0.0001
0
1 month 0
Extreme 0.0001
0
Current year 0
Extreme 1.0E-6
0.01
1 year 0
Extreme 1.0E-6
0.01
3 years 0
Extreme 1.0E-6
8.17
5 years 0
Extreme 1.0E-6
43.3
10 years 0
Extreme 1.0E-6
243.75
Date Insider Type Main position Quantity % Market Cap. Importance
2/12/24 Sell

Chief Executive Officer

37,070 0.1382%
25/11/24 Sell

Chief Executive Officer

134,713 0.5025%
19/11/24 Sell

Chief Financial Officer

46,657 0.1740%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-80.00%-100.00% 2.68K
-2.49%-3.76%+53.38%+62.10% 63.66B
-0.63%-2.91%+6.55%+89.34% 58.56B
-2.37%-2.22%+21.77%+84.58% 54.19B
-2.19%-6.15%+12.43%+111.40% 44.66B
-1.89%-7.28%+9.30%+18.50% 40.51B
-0.93%-0.47%+19.34%+41.83% 36.27B
+1.11%-6.44%+127.46%+675.37% 34.87B
-0.80%+0.61%+76.27%+61.80% 32.26B
-2.17%+16.65%-28.89%+479.93% 31.01B
Average -1.24%-1.09%+21.76%+152.49% 40B
Weighted average by Cap. -1.48%-1.85%+31.83%+155.14%

Financials

2022 2023
Net sales 14.88M 13.55M 12.49M 11.36M 21.31M 1.38B 22.4M 152M 60.41M 753M 55.83M 54.65M 2.36B 9.94M 9.05M 8.34M 7.59M 14.23M 920M 14.96M 101M 40.34M 503M 37.28M 36.49M 1.58B
Net income -94.65M -86.21M -79.44M -72.26M -136M -8.76B -142M -967M -384M -4.79B -355M -348M -15.02B -165M -150M -138M -126M -236M -15.24B -248M -1.68B -668M -8.32B -617M -604M -26.12B
Net Debt -139M -126M -116M -106M -199M -12.85B -209M -1.42B -563M -7.02B -521M -510M -22.02B -77.45M -70.54M -65M -59.13M -111M -7.17B -117M -791M -314M -3.92B -291M -284M -12.29B
Projected Income Statement - Annual - Syros Pharmaceuticals, Inc.
Logo Syros Pharmaceuticals, Inc.
Syros Pharmaceuticals, Inc. is not engaged in any business activities. The Company is actively engaged in the voluntary delisting process. The Company was previously engaged in developing new standards of care for the frontline treatment of patients with hematologic malignancies.
Employees
68
Date Price Change Volume
20/11/26 USD 0.000100 0.00% 1,273
19/11/26 USD 0.000100 0.00% 2,488
18/11/26 USD 0.000100 0.00% 9,653
17/11/26 USD 0.000100 0.00% 2,585
16/11/26 USD 0.000100 0.00% 2,244
  1. Stock Market
  2. Stocks
  3. SYRS Stock